The genome organizer, special AT-rich sequence-binding protein-1 (Satb1), plays a pivotal role in the regulation of global gene networks in a cell type-dependent manner and is indispensable for the development of multiple cell types, including mature CD4 + T, CD8 + T, and Foxp3 + regulatory T cells in the thymus. However, it remains unknown how the differentiation and effector program of the Th subsets in the periphery are regulated by Satb1.
I nterleukin-17 (IL-17)-producing T-helper 17 (Th17) cells play dichotomous roles in the host defense against pathogens at mucosal surfaces and in the pathogenesis of many inflammatory and autoimmune diseases, such as psoriasis, inflammatory bowel disease, rheumatoid arthritis, and multiple sclerosis [1] [2] [3] [4] [5] [6] [7] . Th17 cell differentiation from naive T cells is initiated by transforming growth factor β1 (TGFβ1) and IL-6 and it is further stabilized by environmental cues including cytokines such as IL-1β, IL-23, ligands for the aryl hydrocarbon receptor, hypoxia, and a high sodium chloride concentration [8] [9] [10] [11] [12] [13] [14] [15] [16] . Thus, the terminal differentiation and effector functions of Th17 cells are tightly regulated by intrinsic and extrinsic cues in local tissue environments.
Th17 cells exhibit a high degree of functional heterogeneity. The pathogenic effector program of Th17 cells is induced by IL-23 signaling and is characterized by GM-CSF production [17] [18] [19] . Induction of Th17 cells by TGF-β1 and IL-6 in vitro is not sufficient to cause autoimmune tissue injury in experimental 
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autoimmune encephalomyelitis (EAE), but when induced by IL-1β, IL-6, and IL-23 or TGF-β3, Th17 cells trigger EAE, consistent with the critical roles of IL-23 signaling in the terminal differentiation of Th17 cells 17, [20] [21] [22] [23] . Furthermore, GM-CSF has been identified as a pathogenic signature cytokine of Th17 cells. Driven by IL-1β and IL-23-mediated signaling events along with transcription factor, RORγt, GM-CSF causes local tissue inflammation by recruiting inflammatory myeloid cells 18, 19, [24] [25] [26] . Recent transcriptomic studies have attempted to capture the true physiological state of pathogenicity by using ex vivo Th17 cells and identified Gpr65, Toso, and Plzp as novel genes promoting Th17 pathogenicity and CD5 antigen-like (CD5L) as a repressor of Th17 cell-mediated disease 27, 28 . However, apart from the identification of these various determinants of Th17 pathogenicity, a cohesive molecular mechanism that allows for the distinct functioning of pathogenic and non-pathogenic Th17 cells remains to be identified.
Here, we identified special AT-rich binding protein 1 (Satb1), a genome organizer, as a crucial regulator of the pathogenic function of encephalitogenic tissue Th17 cells. We found that Satb1 is dispensable for the differentiation and non-pathogenic function of Th17 cells in the gut but plays a pivotal role in the effector functions of pathogenic Th17 cells, including GM-CSF production via regulation of Bhlhe40 and PD-1 expression in EAE mice. Moreover, gene expression in Th17 cells from the gut and inflamed spinal cord is differentially regulated by Satb1. Thus, our results indicate that inflammatory cues modulate Satb1 to control the specific effector program of tissue Th17 cells.
Results
Satb1 is dispensable for non-pathogenic Th17 cells. Since Satbldeficient mice exhibit post-natal lethality 29 , we generated Thpok Cre Satb1 fl/fl mice in which Satbl is conditionally deleted in CD4 + CD8 − thymocytes and peripheral CD4 + T cells 30 . To investigate the differentiation and function of Th17 cells under steady-state conditions, we conducted ex vivo analysis of cells from Thpok Cre Satb1 wt/wt and Thpok Cre Satb1 fl/fl mice. Satb1 was highly expressed in CD4 + CD8 + thymocytes, as previously reported [31] [32] [33] [34] , and the expression was dramatically decreased in peripheral CD8 + T and CD4 + T cells, including CD25 − CD44 low CD4 + naive T, CD25 high CD4 + regulatory T (Treg), and CD25 − CD44 high CD4 + effector T cells. Satb1 expression was also decreased in Peyer's patches (PPs) eYFP + CD4 + T (Th17) cells purified from an Il17a Cre R26R eYFP fate reporter strain 35 (Fig. 1a and Supplementary Fig. 6a and 6c for gating strategies). Thpok Cre Satb1 fl/fl mice had the normal numbers of CD4 + CD8 + , CD4 + CD8 − , and CD4 − CD8 + thymocytes and the similar frequencies of IL-17-producing CD4 + T cells in lymph nodes (LNs) and PPs compared with Thpok Cre Satb1 wt/wt mice (Fig. 1b, c) . Upon adoptive transfer into Rag2 −/− mice, naive T cells from Thpok Cre Satb1 fl/fl mice differentiated into IL-17-or IFN-γ-producing Th cells with the same efficiency as cells from Thpok Cre Satb1 wt/wt mice after homeostatic proliferation ( Fig. 1d ). By culturing naive CD4 + T cells from Thpok Cre Satb1 fl/fl and Thpok Cre Satb1 wt/wt mice, we further examined whether Satb1 was required for the differentiation of Th1, Th2, Th17, and induced Treg (iTreg) subsets in vitro. Although Satb1 expression was relatively increased under Th17 culture conditions ( Supplementary Fig. 1 ), the differentiation of IFN-γ-, IL-4-, IL-17-, and Foxp3-expressing CD4 + T cells was not dependent on Satb1 expression in naive T cells ( Fig. 1e ). Although it was previously reported that the knockdown of Satb1 in human CD4 + T cells by siRNA reduced Th2 differentiation 36 , the difference between our result and the report may be attributed to different methods or species we used. We also confirmed that there was the normal differentiation of Th17 cells in Thpok Cre Satb1 fl/fl mice immunized with MOG peptide emulsified in complete Freund's adjuvant (CFA) ( Fig. 1f ). Collectively, these results indicate that Satb1 is dispensable for the differentiation of Th17 cells in vivo and for the induction of the Th17 subset in vitro.
Satb1 regulates the pathogenic function of Th17 cells in EAE.
We next investigated the role of Satb1 in the effector functions of Th17 cells in EAE, an animal model of multiple sclerosis 37, 38 . To determine if Satb1 had a specific role in Th17 cells at the effector phase, we crossed Satb1 fl/fl mice with Il17a Cre R26R eYFP mice to generate Il17a Cre R26R eYFP Satb1 fl/fl conditional knockout mice, in which Cre-mediated deletion of Satb1 occurs in Th17 cells upon their differentiation into IL-17-expressing eYFP + CD4 + T cells. We refer to these mice as Th17 Satb1KO henceforth. We immunized them with MOG peptide in CFA to induce EAE 35, 39 . Notably, Th17 Satb1KO mice were resistant to the development of EAE with fewer eYFP + Th17 cells infiltrating the spinal cord compared with control (Il17a Cre R26R eYFP Satb1 wt/wt ) mice (Fig. 2a-c and Table 1 ). To examine any defects in the effector functions of Th17 cells lacking Satb1, we analyzed the migration and production of cytokines by Th17 cells from Th17 Satb1KO and control mice with the same clinical score. Consistent with the normal development of Th17 cells in the absence of Satb1 expression ( Fig. 1 ), the loss of Satb1 did not significantly affect the differentiation or expansion of Th17 cells in the draining LNs and the migration of Th17 cells into the spinal cord with the same EAE clinical score ( Fig. 2d, e ). Th17 cells lacking Satb1 expressed IFN-γ, IL-2, and IL-17 at levels similar to control cells, but showed impaired production of GM-CSF, a key pathogenic cytokine of the disease 18, 19 (Fig. 2f ). Defective secretion of GM-CSF in Satb1-deficient Th17 cells was confirmed by re-stimulation with an anti-CD3 monoclonal antibody ( Fig. 2g and Supplementary Fig. 6b for gating strategies). IL-10, a hallmark of non-pathogenic Th17 cells 17, 40, 41 , was not secreted by control or Satb1-deficient Th17 cells, even upon anti-CD3 re-stimulation ( Fig. 2f, g) .
Th17 cells from the draining LNs of control EAE mice had significantly higher levels of Satb1 than those from the PPs Fig. 2h ). In vitro re-stimulation of draining LN Th17 cells from control EAE mice with IL-23, but not IL-1β and IL-6 increased Satb1 expression, whereas TGF-β restrained its effect, consistent with the previous report 42 (Fig. 2i ).
Collectively, these results suggest that Satb1 does not affect the maintenance and migratory capacity of Th17 cells to inflamed tissues, but Satb1 expression is increased upon IL-23 stimulation and plays a pivotal role in the pathogenicity of EAE and effector 
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Genes Satb1 does not affect activation markers in Th17 cells. Given that Satb1 influences the regulation of multiple genes in T cells and their precursors 29, 39, 43 , we compared the activation and proliferation profile of eYFP + Th17 cells from Th17 Satb1KO and control mice after EAE induction. The expression levels of Ki-67 and Bcl-2 in Th17 cells from draining LNs and the spinal cord were comparable between the two mouse strains (Fig. 3a, b) . Further, the absence of Satb1 in effector Th17 cells did not affect the expression of surface markers CD25, CD44, CD69, CD103, GITR, ICOS, and KLRG1 ( Fig. 3c ), indicating that Satb1 does not regulate these activation-, proliferation-, and survival-associated genes in effector Th17 cells.
Satb1 regulates pathogenic gene expression in Th17 cells. Since Satb1-deficient Th17 cells exhibited no changes in the expression
of key activation and proliferation markers ( Fig. 3 ), global expression profiling was conducted to identify other dysregulated genes associated with the loss of Satb1. To this end, eYFP + Th17 cells were sorted from the spinal cords of Th17 Satb1KO and control mice at the peak of the disease after EAE induction and were subjected to gene expression analysis by RNA-seq. As shown in Fig. 3 , Satb1 deficiency showed limited effect on global gene expression. We identified 192 differentially expressed genes, with 92 down-regulated and 100 up-regulated genes, in Satb1-deficient Th17 cells compared with control Th17 cells ( Fig. 4a ). Among these, we validated Satb1 and 12 other potential candidates associated with Th17 pathogenicity by q-PCR (Fig. 4b, c ). Of the 12 genes, 3 genes (Bhlhe40, Csf2, and Nfkbiz) were significantly down-regulated in Satb1-deficient Th17 cells from both the draining LNs and spinal cord, 1 gene (Ikzf3) was significantly upregulated in Satb1-deficient Th17 cells from both the draining LNs and spinal cord, and 1 gene (Pdcd1) was significantly upregulated in Satb1-deficient Th17 cells from only the spinal cord ( Fig. 4c ). Csf2 encodes GM-CSF and Bhlhe40 encodes a key transcription factor driving Csf2 transcription 44, 45 ; therefore, their down-regulation is consistent with the impaired production of GM-CSF by Satb1-deficient Th17 cells ( Fig. 2f, g) . Nfkbiz encodes a transcriptional coregulator that acts with RORγt to regulate IL-17 expression in Th17 cells 46 ; the effect was likely to be limited because of the normal development of Th17 cells and IL-17 production in the absence of Satb1. By contrast, the expression of Ikzf3, which promotes the development of Th17 cells by repressing IL-2 production 47 , was significantly higher in Satb1-deficient Th17 cells despite their ability to secrete IL-2 ( Fig. 2f ). There was no significant difference in the expression of genes encoding Th17 signature cytokines and regulators such as Hif1a, Il17a, Il22, Il23r, Prdm1, and Rorc confirmed by q-PCR (Fig. 4b, c) . Notably, the differential regulation of Bhlhe40 and Pdcd1, which encodes the inhibitory receptor PD-1, was not seen in non-pathogenic Th17 cells in PPs, which barely secreted GM-CSF ( Supplementary Fig. 2a-c) . Gene expression analysis revealed that the majority of genes dysregulated in the absence of Satb1 was not overlapped between non-pathogenic and pathogenic Th17 cells.~150 genes were up-regulated and down-regulated in non-pathogenic Satb1-deficient Th17 cells, but did not affect the signature cytokine Il17 and Il22 expression and transcription factors including Bhlhe40 ( Fig. 4d and Supplementary Fig. 2d ).
The specific role of the overlapped genes (10 down-regulated and 30 up-regulated) in other immune reactions remains to be defined in the future study ( Table 2) . Taken together, these results indicate that Satb1 specifically regulates the divergent gene expression in non-pathogenic and pathogenic Th17 cells at different locations under homeostatic and inflammatory conditions.
Bhlhe40 restores the pathogenicity of Satb1 −/− Th17 cells. We next focused on Bhlhe40 as a possible regulatory factor of Satb1mediated GM-CSF production. The expression of Bhlhe40 was higher in pathogenic Th17 cells from the draining LNs of control EAE mice than in non-pathogenic Th17 cells from PPs and CD25 − CD44 high CD4 + effector T cells (Fig. 5a ), correlating with the increased expression of Satb1 in Th17 cells from the draining LNs of control EAE mice (Fig. 2h) . To examine the function of Bhlhe40 in Satb1-deficient Th17 cells in which Bhlhe40 expression was decreased, we constructed a retroviral vector to ectopically express Bhlhe40 and NGFR as a reporter gene and validated the induction of Bhlhe40 in NGFR + T cells after Bhlhe40 was transduced in naive CD4 + T cells under Th0 conditions (Fig. 5b) . We then addressed whether the Satb1-Bhlhe40 axis plays a critical role in the pathogenesis of Th17 cells. Retroviral transduction of a Bhlhe40-expressing vector into Satb1-deficient CD4 + T cells, followed by adoptive transfer into Rag2 −/− mice in which EAE was induced 2 weeks later, substantially restored the pathogenic function of Satb1-deficient CD4 + T cells ( Fig. 5c and Supplementary Fig. 6d for gating strategies), as well as GM-CSF expression in the draining LNs ( Fig. 5d ) and spinal cord (Fig. 5e ) of EAE recipient mice. Collectively, these results indicate that Satb1 regulates the pathogenic function of Th17 cells and GM-CSF production in part via Bhlhe40. Table 2 The list of the overlapped genes shown in Fig. 4d 10 Down-regulated genes 30 Up-regulated genes 5430421N21Rik
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The list of the overlapped genes down-regulated or up-regulated between non-pathogenic (PP eYFP + CD4 + ) Th17 cells and pathogenic (eYFP + CD4 + ) Th17 cells from the inflamed spinal cord of Th17 Satb1KO mice after EAE induction. eYFP + Th17 cells were sorted at the peak of the disease (14 days after EAE induction) NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-08404-w ARTICLE Satb1 inhibits PD-1 expression in effector Th17 cells. In an attempt to characterize the impaired effector functions of Th17 cells in the absence of Satb1, we found that the production of GM-CSF, IFN-γ, IL-2, and TNF, but not IL-17, was greatly impaired when Satb1-deficient Th17 cells from the inflamed spinal cord of Th17 Satb1KO mice were cultured with bone marrow-derived dendritic cells (BMDCs) in the presence of MOG peptide while GM-CSF and IL-2 were also affected in Satb1-deficient Th17 cells from the spleen (Fig. 6a and Supplementary Fig. 3a ). Since the production of IFN-γ, IL-2, and TNF upon re-stimulation with anti-CD3 was comparable between Satb1-deficient and control Th17 cells (Fig. 2g) , and the communication between dendritic cells and T cells is based on receptor-ligand interactions that regulate immune checkpoints, BMDC-mediated suppression of effector cytokines prompted us to investigate the expression of immune checkpoint molecules by Th17 cells 48 . Satb1-deficient Th17 cells from the inflamed spinal cord, but not the draining LNs and spleen of EAE mice, expressed higher levels of PD-1 than control Th17 cells in accordance with the up-regulation of Pdcd-1 observed in Satb1-deficient Th17 cells and the similar finding reported in activated T cells 42 (Fig. 4b, c and 6b, c and Supplementary Fig. 3b ). The expression of other immune checkpoint molecules, such as CTLA-4, LAG3, TIGIT, and Tim3, was unchanged in Satb1-deficient Th17 cells from the spinal cord, draining LNs and spleen ( Fig. 6b and Supplementary  Fig. 3b ).
We next examined whether the up-regulation of PD-1 by Satb1-deficient Th17 cells is related to the decreased severity of EAE seen in Th17 Satb1KO mice ( Fig. 2a ). To this end, anti-PD-1 blocking monoclonal antibody was administered to mice following EAE induction. Th17 Satb1KO mice that received the anti-PD-1 antibody exhibited increased severity of disease compared to Th17 Satb1KO mice that received the isotypematched control antibody. Disease severity in control mice was comparable between anti-PD-1 and control antibody-treated mice (Fig. 6d ). Moreover, when Th17 cells from control or Th17 Satb1KO inflamed spinal cords were co-cultured with BMDCs in the presence of MOG peptide and the anti-PD-1 antibody, the production of IL-2 and IL-17 by control or Satb1-deficient Th17 cells was significantly enhanced, whereas the production of GM-CSF, IFN-γ, IL-1β, IL-6, IL-23, and TNF was unaffected by the presence of the anti-PD-1 antibody ( Fig. 6e and Supplementary Fig. 3c ), indicating that PD-1 signaling predominantly regulates IL-2 and IL-17 production, but not all the effector cytokines including GM-CSF, which appears to be regulated by Bhlhe40 in Th17 cells. Taken together, these results indicate that Satb1-mediated regulation of PD-1 expression controls specific effector cytokines including IL-17 by Th17 cells and contributes to the pathogenesis of EAE.
Satb1 binds to the promoter region at the Bhlhe40 locus. To gain further insight into Satb1-dependent transcriptional regulation in Th17 cells, we investigated genome-wide Satb1-binding sites in Th17 cells using chromatin immunoprecipitation sequencing (ChIP-seq) analyses with an anti-Satb1 monoclonal antibody. In vitro polarized Satb1-deficient eYFP + Th17 cells showed higher levels of PD-1 than control eYFP + Th17 cells ( Supplementary Fig. 4a) , consistent with increased PD-1 expression observed in Th17 cells from the inflamed spinal cords (Fig. 6b ). Using eYFP + Th17 cells from Il17a Cre R26R eYFP Satb1 wt/wt mice, we analyzed the Satb1 binding sites at affected gene loci in Th17 cells (loci identified in Fig. 4a ). Among the gene loci analyzed (Bhlhe40, Pdcd1, Csf2, Hif1a, Ikzf3, Nfkbiz, and Prdm1), Satb1 specifically bound only to the active promoter region of the Bhlhe40 locus, which was marked by H3K27 acetylation and this association of Satb1 with the enhancer region was also confirmed by quantitative ChIP-PCR (Fig. 7a, b and Supplementary Fig. 4b ). However, this active enhancer mark of H3K27ac in Th17 cells could be maintained independently of Satb1. Notably, there was no direct evidence of Satb1 binding on the Pdcd1, Csf2, Hif1a, Ikzf3, Nfkbiz, and Prdm1 loci. These results suggest that there are direct and context-dependent gene regulations by Satb1 that control GM-CSF and PD-1 expression in encephalitogenic tissue Th17 cells, but Satb1 is not involved in the epigenetic modification of the Bhlhe40 locus.
Discussion
In this study, we show that the pathogenic effector program, but not the differentiation and non-pathogenic functions of tissue Th17 cells, is specifically controlled by the genome organizer Satb1. Satb1-mediated regulation of Bhlhe40 and PD-1 controls Th17 pathogenicity in part by IL-17 and GM-CSF production in the central nervous system during autoimmune disease. Notably, Satb1 differentially controlled the gene expression profiles in nonpathogenic and pathogenic Th17 cells isolated from the gut and inflamed tissue, respectively. Therefore, Satb1 shaped the divergent gene expression in tissue Th17 cells in an environmental context-dependent manner.
Satb1 regulates a specific set of gene expression in effector Th17 cells under inflammatory conditions. It is well appreciated that Satb1 is regulated by TCR signaling and highly expressed by immature thymocytes and plays a crucial role under physiological conditions in the specification and function of T cell lineages, including Foxp3 + Tregs developed in the thymus, by regulating the chromatin-loop architecture 33, 34, 46, 49 . It is of note that the expression levels of Satb1 are greatly reduced in mature T cells populating the periphery, implying that peripheral T cell subsets may decrease the dependency of Satb1 on their functions, and, for instance, its expression in Tregs has little impact on their functions and the Treg-mediated immunological self-tolerance in the periphery 29, 32, 34, 39, [49] [50] [51] . Although the knockdown of Satb1 reduced IL-17 expression in in vitro-polarized Th17 cells 52 and the overexpression of SATB1 was observed in patients with anaplastic T lymphoma and increased Th17-associated genes 53 , the role of Satb1 in the differentiation and function of effector Th17 cells in vivo in autoimmune reactions remained elusive. Our results indicate that Satb1 is dispensable for the differentiation and cytokine production of gut Th17 cells, but significantly contributes to inflammatory properties of tissue Th17 cells, consistent with transcriptomic analysis revealing that the absence of Satb1 expression did not affect the fundamental gene expression profile in Th17 cells, unlike immature T cells and its precursors, but specifically controlled a limited number of effector genes in pathogenic Th17 cells in inflamed tissues in EAE mice. Hence, in vivo phenotypes of Th17 cells, such as the activation status, migratory capacity, and maintenance of RORγt and IL-17 expression, were not significantly affected by Satb1 whereas among Bhlhe40, Blimp-1, GM-CSF, JunB, Gpr65, and Toso, as key pathogenic factors expressed by Th17 cells in EAE 18, 19, 27, 44, 45, 54, 55 , Satb1 specifically regulates GM-CSF in part via Bhlhe40 expression and down-regulates PD-1 expression for the acquisition of a pathogenic mode of Th17 cells. The gene expression of Bhlhe40 and PD-1 in effector T cells is controlled upon T cell activation and external environmental signals. CD28 stimulation is known to induce Bhlhe40 expression in T cells and IL-1R signaling further enhances it in Th17 cells 44, 56 . Given that Satb1-deficient Th17 cells express normal levels of IL-1R, reduced expression of Bhlhe40 may be due to disruption of its transcriptional machinery mediated by a transcription factor complex with Satb1 downstream of IL-1R signaling pathway, resulting in impaired GM-CSF production by effector Th17 cells. Notably, the dysregulation of PD-1 by Satb1 was only observed in Th17 cells from the spinal cord in EAE mice, but not in those from the draining LNs and PPs. This Satb1-mediated regulation of PD-1 during inflammation is likely to be indirect since no direct binding of Satb1 to the Pdcd1 promoter region was detected. Inhibition of PD-1 occurs in CD8 + T cells through the recruitment of a nucleosome remodeling deacetylase repression complex by Satb1 and is abrogated in tumor micro-environments 42 , suggesting that similar mechanisms may operate in Th17 cells in inflamed tissues of EAE. Because Satb1 alone is not sufficient to change the expression levels of PD-1, external environmental cues such as chronic IL-23 signaling in inflamed tissues may be necessary to not only upregulate the expression of Satb1, but also to modulate a mode of Satb1 function and dynamic chromatin architecture, shifting Th17 cells toward a pathogenic profile. On the other hand, in vitro treatment of TGF-β increased Pdcd1 expression in Th17 cells, suggesting that TGF-β enriched environment such as the intestine may maintain Satb1 expression low and in turn prevent the down-regulation of PD-1 in non-pathogenic Th17 cells ( Supplementary Fig. 5 ). Further studies are necessary to investigate how particular environmental signals and specific co-factors dictate Satb1 function to regulate the effector profile in Th17 cells, and how Satb1-mediated chromatin loop organization occurs in gene loci related to Th17 cell pathogenicity.
Because Satb1 is a key regulator of Th17 pathogenicity and its GM-CSF production in autoimmune disease in mice, manipulating Satb1 gene expression or function may be a therapeutic target for various autoimmune diseases in light of accumulating evidence that GM-CSF-targeting treatments have been reported to be effective in clinical trials for patients with rheumatoid arthritis and multiple sclerosis [57] [58] [59] [60] [61] . Furthermore, a single nucleotide polymorphism (rs11719975) in a region near the human SATB1 gene has been recently associated with multiple sclerosis, suggesting an unappreciated link between SATB1 and the pathogenic function of effector T cells in the central nervous system of the patients 62 . However, the SATB1-mediated gene expression and effector program of human Th17 cells could differ in patients with different inflammatory diseases and at different ARTICLE clinical stages, and should carefully be assessed using clinical samples in the future study. Together, our findings, in addition to providing novel insights into the molecular mechanisms underlying the pathogenic program of tissue Th17 cells in mice, may help design novel immunotherapeutic approaches such as small molecule modifiers of Satb1 for the treatment of autoimmune diseases.
Methods
Mice. C57BL/6J mice were purchased from CLEA Japan. Rag2 −/− mice have been previously described 63 . To generate Satb1 conditional knockout mice, we crossed Satb1 fl/fl mice with Il17a Cre R26R eYFP or Thpok Cre mice, in which Satb1 is depleted in IL-17-producing T cells or peripheral CD4 + T cells, respectively 35, 39, 46, 56 . All the mice used were on a C57BL/6 background and were maintained under SPF conditions in the animal facility at the Institute for Frontier Life and Medical Sciences, Kyoto University. Six to twelve-week-old mice were used for most of the experiments. Four-week-old mice were used for the analysis of thymocytes. All the experiments were approved by the animal ethical committee of the Institute for Frontier Life and Medical Sciences, Kyoto University and were performed in accordance with institutional guidelines.
Antibodies. The following antibodies were used for the flow cytometry analysis and cell sorting: CD4 (1:400, RM4-5, #553051), CD8 (1:400, 53-6.7, #553033), Cell preparation. For the preparation of double-positive (DP), CD4 + singlepositive (SP), and CD8 + SP thymocytes, CD4 + CD8 + , CD4 + CD8 − , and CD4 − CD8 + thymocytes, respectively, were sorted using FACSAria (BD Bioscience). Peripheral naive (CD44 low CD25 − CD4 + ) T cells, regulatory (CD25 high CD4 + ) T cells and effector (CD44 high CD25 − CD4 + ) T cells were sorted from LNs and the spleen. CD4 + eYFP + T cells from the PPs of non-immunized mice or the spinal cord of EAE mice at the peak of the disease (14 ± 3 days after EAE induction) were sorted by FACSAria as non-pathogenic or pathogenic Th17 cells, respectively. CD4 + eYFP + T cells from draining LNs were sorted on day 7 after EAE induction. The pathogenic Th17 cells were prepared by mashing the spinal cord through a 70-μm mesh filter, followed by 36.5% Percoll separation.
Cell culture. Purified CD25 − CD44 low CD4 + naive T cells were stimulated with plate-bound anti-CD3 (1 μg/ml; 2C11; BD Biosciences) and anti-CD28 (5 μg/ml; 37.51; BD Biosciences) in IMDM supplemented with 10% FCS, 100 U/ml penicillin, 100 μg/ml streptomycin, 50 μM 2-mercaptoethanol and 2 mM L-glutamine in the presence of rmIL-12 (10 ng/ml, R&D Systems) for Th1, rmIL-4 (10 ng/ml, R&D Systems) and anti-IFNγ (10 μg/ml, Biolegend) for Th2, rhTGF-β (10 ng/ml, R&D Systems) for iTregs, and rhTGF-β (1 ng/ml), rmIL-6 (20 ng/ml, R&D Systems) and rmIL-1β (20 ng/ml, R&D Systems) for Th17 conditions and intracellular cytokine and Foxp3 staining was performed after 72-96 h. In brief, for the cytokine staining, cells were restimulated for 2.5 h with PMA (500 ng/ml) and ionomycin (500 ng/ml) in the presence of brefeldin A (1 μg/ml). Fixation and permeabilization were followed by intracellular staining according to the manufacturer's instruction (Thermo Fisher). Purified eYFP + Th17 cells (1 × 10 6 /ml) from the draining LNs of the EAE mice were stimulated with CD3/CD28 Dynabeads (Thermo Fisher) in the presence or absence of rmIL-1β (20 ng/ml, R&D Systems), rmIL-6 (20 ng/ml, R&D Systems), rmIL-23 (100 ng/ml, R&D Systems) or rhTGF-β (10 ng/ml) for 24 h, and the cells were harvested for quantitative RT-PCR. Purified eYFP + Th17 cells (5 × 10 4 /ml) from the spinal cord of EAE mice were stimulated with plate-bound anti-CD3 (1 μg/ml) or BMDCs (5 × 10 4 /ml) in the presence of MOG peptide (50 μg/ml) and anti-PD-1 mAb (20 μg/ml; 29F.1A12 from Bio X cell) or an isotypematched control IgG2a (20 μg/ml; C1.18.4 from Bio X cell) for 24 h and cytokine concentrations in the supernatants were determined using a Cytometric Bead Array (BD Biosciences).
Generation of bone marrow-derived dendritic cells (BMDCs).
Single cell suspensions of bone marrow cells from 4-8-week old C57BL/6J mice were prepared from the femur and tibia and subjected to red blood cell lysis with buffered ammonium chloride solution. Cells were then cultured at 1 × 10 6 /ml in RPMI supplemented with 10% fetal calf serum, penicillin, streptomycin, and 2-ME in the presence of GM-CSF (20 ng/ml) (R&D Systems). All media was removed and replaced with fresh media containing GM-CSF on day 3 and day 5. By day 7, more than 80% of the resulting cells expressed CD11b and class II MHC and were used as antigen presenting cells.
EAE.
In brief, mice were injected subcutaneously at two sites with an emulsion of 100 μl CFA and 250 μg MOG peptide (amino acids . Mice received 200 ng Bordetella pertussis (Calbiochem) intraperitoneally at day 0 and day 2 after EAE induction. An anti-PD-1 mAb (200 μg/mouse; 29F.1A12 from Bio X Cell) or a control IgG2a (200 μg/mouse; C1.18.4 from Bio X Cell) antibody was intraperitoneally injected three times a week beginning at day 5 after EAE induction. The clinical scores were assessed daily as follows: 0, unaffected; 1, flaccid tail; 2, impaired righting reflex and/or gait; 3, partial hind limb paralysis; 4, total hind limb paralysis; and 5, total hind limb paralysis with partial forelimb paralysis.
Quantitative RT-PCR. Total RNA was extracted and reverse-transcribed using TRIzol Reagent (Life Technologies) and SuperScript VILO (Invitrogen) according to the manufacturer's instruction. Quantitative RT-PCR was performed using TaqMan Gene Expression Assays (Thermo Fisher) and a Light cycler 480 (Roche) for the following genes: Bhlhe40 (Mm00478593_m1), Csf2 (Mm01290062_m1), Foxp3 (Mm00475162_m1), Hif1a (Mm00468869_m1), Ikzf3 (Mm01306721_m1), Ifnγ (Mm01168134_m1), Il4 (Mm00445259_m1), Il17a (Mm00439618_m1), Il22 (Mm00444241_m1), Il23r (Mm00519943_m1), Nfkbiz (Mm00600522_m1), Pdcd1 (Mm01285676_m1), Prdm1 (Mm00476128_m1), Rorc (Mm01261022_m1), Satb1 (Mm01268937_m1), Tbx21 (Mm00450960_m1), and Hprt (Mm03024075_m1), as a housekeeping gene. The target gene expression was calculated by the comparative method for relative quantification after normalization to Hprt expression.
Cloning of Bhlhe40 and retroviral transduction. Murine Bhlhe40 was amplified using 5′-TACGTAATGGAACGGATCCCCAGCGC-3′ and 5′-GTCGACT-TAGTCTTTGGTTTCTACGT-3′ oligos and was cloned into the retroviral GCDN samI/N vector containing NGFR. The generation of retrovirus and the subsequent retroviral transduction were performed. In brief, retroviral plasmids were transfected into Plat-E cells using Fugene 6 (Promega) according to the manufacturer's instructions and retrovirus-containing supernatants were harvested 48 h after transfection. Magnetically sorted CD4 + T cells were activated with plate-coated anti-CD3/CD28 for day 3 and the cells were spin-infected with retroviral supernatants containing 2.5 μg/ml polybrene for 90 min at 32°C in 24-well plates at 1220g. The transduction efficiencies were assessed for NGFR expression, and the NGFR + CD4 + T cells were sorted on day 5 after transduction.
ChIP-sequencing. A total of 1-2.5 × 10 6 Th0 or eYFP + Th17 cells were induced in vitro under Th0 or Th17 culture conditions, and the cells were sorted for ChIPseq analysis 34 . In brief, sorted cells were cross-linked using 1% formaldehyde and lysed. Cross-linked DNA was fragmented by sonication and the lysate was incubated with anti-H3K27ac (GeneTex, GEX60815) or anti-Satb1 (Abcam, ab70004) antibodies (Thermo Fisher) captured by magnetic beads, followed by elution, reverse cross-link, and purification for ChIP-seq analysis according to the manufacturer's instructions. The ChIP-seq reads were mapped to the mouse genome mm9 Illumina iGenomes (http://support.illumina.com/sequencing/ sequencing_software/igenome.html) using Bowtie2 (version 2.2.1), and the ChIPseq peaks, normalized by total mapped read counts, were visualized in Integrative Genomics Viewer (Broad Institute).
Quantitative ChIP-PCR. A total of 1-2.5 × 10 6 Th0 or eYFP + Th17 cells were induced in vitro under Th0 or Th17 culture conditions, and the cells were sorted for ChIP-qPCR. ChIP-qPCR analysis was performed with anti-Satb1 (Abcam, ab70004) antibody and control IgG (Abcam, ab171870) and the primers specific for the active promoter region of Bhlhe40 (5′-CAATGACGACTGACCCACCA-3′ and 5′-CCCTGCAAGTTCGGAGAGTT-3′).
RNA-sequencing. A total of 2 × 10 4 eYFP + Th17 cells from the spinal cord of the control and Th17 Satb1KO EAE mice were sorted at the peak of the disease (14 ± 3 days after EAE induction) for RNA-seq analysis in duplicate. A total of 1 × 10 4 eYFP + Th17 cells from the control and Th17 Satb1KO PPs of non-immunized mice were sorted for RNA-seq analysis in quadruplicate. In brief, total RNA was extracted and reverse-transcribed using RNeasy Micro Kit (Qiagen) and RNA-seq was performed using a SMART-seq v4 Ultra Low Input RNA Kit for Sequencing (Clonetech). The sequences were mapped to the mouse genome version mm9 using Hisat2. Differential gene expression analyses were performed using DESeq2 package in R (version 3.1.2) on tag counts obtained by HT-seq (version 0.6.1). The differentially expressed genes were defined with FDR less than 0.05.
Statistical analysis. Two-tailed Student's t-test was used for most of the statistical analyses (GraphPad Prism), and a P value of <0.05 was considered statistically significant. The clinical scores of EAE between each group were analyzed by twoway ANOVA with Bonferroni's post-test.
